# Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20

> **NCT03605238** · PHASE1 · WITHDRAWN · sponsor: **Chinese PLA General Hospital**

## Conditions studied

- Neuromyelitis Optica Spectrum Disorder

## Interventions

- **BIOLOGICAL:** Corticosteroids & tanCART19/20

## Key facts

- **NCT ID:** NCT03605238
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-08-15
- **Primary completion:** 2019-08-15
- **Final completion:** 2020-08-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** It was hard to recruit patients
- **Last updated:** 2019-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03605238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03605238, "Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03605238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*